Annual report pursuant to Section 13 and 15(d)

Stockholders??? (Deficit) Equity (Details)

v3.22.1
Stockholders’ (Deficit) Equity (Details) - USD ($)
 1 Months Ended 12 Months Ended
Jul. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Stockholders’ (Deficit) Equity (Details) [Line Items]      
Common stock, shares authorized   200,000,000 200,000,000
Common stock par value (in Dollars per share)   $ 0.001 $ 0.001
Purchase of additional warrants shares 5    
Warrants term 5 years 5 years  
Exercise price (in Dollars per share) $ 6 $ 6  
Proceeds of warrants (in Dollars) $ 7,500    
Converted shares   736,773  
Convertible debt shares granted   184,193  
Description of consulting exercised   employees and consultants exercised a total of 383,721 stock options and the Company received $119,000 in proceeds. A portion of these options were exercised early (prior to vesting), and as of December 31, 2021, 76,397 of the options remained unvested. Proceeds received related to the unvested options of $60,000 at December 31, 2021 were included in accrued liabilities on the accompanying balance sheets and will be reclassified to equity as vesting occurs, provided the employees and consultants continue to provide services to the Company. The vested portion of the exercises was 307,317 shares at December 31, 2021.  
Shares issued of investors     33,263
Investors in exchange for cash price     4.21%
Investors exchange of shares     24,627
Preferred stock, shares authorized   10,000,000 10,000,000
Preferred stock, par value (in Dollars per share)   $ 0.001 $ 0.001
Common Stock [Member]      
Stockholders’ (Deficit) Equity (Details) [Line Items]      
Purchase of additional warrants shares 5,000,000    
Common stock price, per share (in Dollars per share) $ 4.99    
Warrants [Member]      
Stockholders’ (Deficit) Equity (Details) [Line Items]      
Purchase of additional warrants shares 600,000    
Shares issued 4,000,000    
Spectrum Pharmaceuticals, Inc. [Member]      
Stockholders’ (Deficit) Equity (Details) [Line Items]      
Purchase of additional warrants shares 438,374